Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
68
PBE Quote, Financials, Valuation and Earnings
Last price:
$82.23
Seasonality move
:
2.97%
Day range:
$82.03 - $82.24
52-week range:
$54.52 - $83.59
Dividend yield:
0.49%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
2.9K
Avg. volume:
6.2K
1-year change:
16.22%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
$82.06 | -- | -- | -- | $0.23 | 0.49% | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
$105.25 | -- | -- | -- | $0.24 | 0.95% | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
$123.25 | -- | -- | -- | $0.03 | 0.03% | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
$89.39 | -- | -- | -- | $0.03 | 0.08% | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
$108.20 | -- | -- | -- | $0.07 | 0.24% | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
$54.29 | -- | -- | -- | $0.10 | 0.93% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 0.859 | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | 0.316 | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | 1.273 | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | 1.031 | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | 0.960 | -- | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
-- | 0.588 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
Invesco Biotechnology & Genome ETF vs. Competitors
-
Which has Higher Returns PBE or PJP?
Invesco Pharmaceuticals ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- -
What do Analysts Say About PBE or PJP?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than Invesco Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 PJPInvesco Pharmaceuticals ETF0 0 0 -
Is PBE or PJP More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.822, which suggesting that the stock is 17.787% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.387%.
-
Which is a Better Dividend Stock PBE or PJP?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.23 per share corresponding to a yield of 0.49%. Invesco Pharmaceuticals ETF offers a yield of 0.95% to investors and pays a quarterly dividend of $0.24 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or PJP?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns PBE or XBI?
State Street SPDR S&P Biotech ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat State Street SPDR S&P Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- XBIState Street SPDR S&P Biotech ETF-- -- -- -
What do Analysts Say About PBE or XBI?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than State Street SPDR S&P Biotech ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than State Street SPDR S&P Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 XBIState Street SPDR S&P Biotech ETF0 0 0 -
Is PBE or XBI More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.822, which suggesting that the stock is 17.787% less volatile than S&P 500. In comparison State Street SPDR S&P Biotech ETF has a beta of 0.931, suggesting its less volatile than the S&P 500 by 6.918%.
-
Which is a Better Dividend Stock PBE or XBI?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.23 per share corresponding to a yield of 0.49%. State Street SPDR S&P Biotech ETF offers a yield of 0.03% to investors and pays a quarterly dividend of $0.03 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. State Street SPDR S&P Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or XBI?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Biotech ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than State Street SPDR S&P Biotech ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while State Street SPDR S&P Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for State Street SPDR S&P Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- XBIState Street SPDR S&P Biotech ETF-- -- -- --
-
Which has Higher Returns PBE or XHE?
State Street SPDR S&P Health Care Equipment ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat State Street SPDR S&P Health Care Equipment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- XHEState Street SPDR S&P Health Care Equipment ETF-- -- -- -
What do Analysts Say About PBE or XHE?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Health Care Equipment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than State Street SPDR S&P Health Care Equipment ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than State Street SPDR S&P Health Care Equipment ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 XHEState Street SPDR S&P Health Care Equipment ETF0 0 0 -
Is PBE or XHE More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.822, which suggesting that the stock is 17.787% less volatile than S&P 500. In comparison State Street SPDR S&P Health Care Equipment ETF has a beta of 1.125, suggesting its more volatile than the S&P 500 by 12.522%.
-
Which is a Better Dividend Stock PBE or XHE?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.23 per share corresponding to a yield of 0.49%. State Street SPDR S&P Health Care Equipment ETF offers a yield of 0.08% to investors and pays a quarterly dividend of $0.03 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. State Street SPDR S&P Health Care Equipment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or XHE?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Health Care Equipment ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than State Street SPDR S&P Health Care Equipment ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while State Street SPDR S&P Health Care Equipment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for State Street SPDR S&P Health Care Equipment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- XHEState Street SPDR S&P Health Care Equipment ETF-- -- -- --
-
Which has Higher Returns PBE or XHS?
State Street SPDR S&P Health Care Services ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat State Street SPDR S&P Health Care Services ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- XHSState Street SPDR S&P Health Care Services ETF-- -- -- -
What do Analysts Say About PBE or XHS?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Health Care Services ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than State Street SPDR S&P Health Care Services ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than State Street SPDR S&P Health Care Services ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 XHSState Street SPDR S&P Health Care Services ETF0 0 0 -
Is PBE or XHS More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.822, which suggesting that the stock is 17.787% less volatile than S&P 500. In comparison State Street SPDR S&P Health Care Services ETF has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.625%.
-
Which is a Better Dividend Stock PBE or XHS?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.23 per share corresponding to a yield of 0.49%. State Street SPDR S&P Health Care Services ETF offers a yield of 0.24% to investors and pays a quarterly dividend of $0.07 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. State Street SPDR S&P Health Care Services ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or XHS?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Health Care Services ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than State Street SPDR S&P Health Care Services ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while State Street SPDR S&P Health Care Services ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for State Street SPDR S&P Health Care Services ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- XHSState Street SPDR S&P Health Care Services ETF-- -- -- --
-
Which has Higher Returns PBE or XPH?
State Street SPDR S&P Pharmaceuticals ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat State Street SPDR S&P Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- -
What do Analysts Say About PBE or XPH?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than State Street SPDR S&P Pharmaceuticals ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than State Street SPDR S&P Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 XPHState Street SPDR S&P Pharmaceuticals ETF0 0 0 -
Is PBE or XPH More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.822, which suggesting that the stock is 17.787% less volatile than S&P 500. In comparison State Street SPDR S&P Pharmaceuticals ETF has a beta of 0.657, suggesting its less volatile than the S&P 500 by 34.268%.
-
Which is a Better Dividend Stock PBE or XPH?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.23 per share corresponding to a yield of 0.49%. State Street SPDR S&P Pharmaceuticals ETF offers a yield of 0.93% to investors and pays a quarterly dividend of $0.10 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. State Street SPDR S&P Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or XPH?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Pharmaceuticals ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than State Street SPDR S&P Pharmaceuticals ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while State Street SPDR S&P Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for State Street SPDR S&P Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
